Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.69 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | MARS1 | P56192 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.41 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30949040 | 1.00 | NPSR1 (0.69) | NPSR1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL30949032 | 0.91 | NPSR1 (0.69) | NPSR1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4111468 | 0.91 | NPSR1 (0.69) | NPSR1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4098478 | 0.90 | CYP1A2 (0.55) | NPSR1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1049705 | 0.90 | CYP1A2 (0.55) | NPSR1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL30949027 | 0.90 | CYP1A2 (0.55) | NPSR1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4097771 | 0.89 | CYP1A2 (0.54) | NPSR1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1049264 | 0.89 | CYP1A2 (0.54) | NPSR1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL30949028 | 0.89 | CYP1A2 (0.54) | NPSR1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1051466 | 0.89 | CYP1A2 (0.81) | NPSR1CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118001272-A | Use of indazoles for treating diseases mediated by activation of inflammatory bodies | 中山大学 | 2024-05-10 | — | — | CN | claimed |
| EP-1786424-A2 | LONIDAMINE ANALOGUES AND THEIR USE IN MALE CONTRACEPTION AND CANCER TREATMENT | The University of Kansas (US) | 2007-05-23 | — | — | EP | claimed |
| US-20060047126-A1 | Lonidamine analogues and their use in male contraception and cancer treatment | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-03-02 | — | — | US | claimed |
| WO-2006023704-A2 | LONIDAMINE ANALOGUES AND THEIR USE IN MALE CONTRACEPTION AND CANCER TREATMENT | UNIVERSITY OF KANSAS (US) | 2006-03-02 | — | — | WO | claimed |
| CN-118001272-A | Use of indazoles for treating diseases mediated by activation of inflammatory bodies | 中山大学 | 2024-05-10 | — | — | CN | disclosed |
| US-20130123296-A1 | LONIDAMINE ANALOGUES FOR FERTILITY MANAGEMENT | THE UNIVERSITY OF KANSAS (US) | 2013-05-16 | — | — | US | disclosed |
| US-8377958-B2 | Lonidamine analogues for fertility management | THE UNIVERSITY OF KANSAS (US) | 2013-02-19 | — | — | US | disclosed |
| US-8377958-B2 | Lonidamine analogues for fertility management | THE UNIVERSITY OF KANSAS (US) | 2013-02-19 | — | — | US | disclosed |
| US-8362031-B2 | Lonidamine analogues and treatment of polycystic kidney disease | UNIVERSITY OF KANSAS (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362031-B2 | Lonidamine analogues and treatment of polycystic kidney disease | UNIVERSITY OF KANSAS (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362031-B2 | Lonidamine analogues and treatment of polycystic kidney disease | UNIVERSITY OF KANSAS (US) | 2013-01-29 | — | — | US | disclosed |
| EP-2502624-A1 | Lonidamine analogues and their use in male contraception and cancer treatment | THE UNIVERSITY OF KANSAS (US) | 2012-09-26 | — | — | EP | disclosed |
| US-20090197911-A1 | LONIDAMINE ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-06 | — | — | US | disclosed |
| US-20090197911-A1 | LONIDAMINE ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-06 | — | — | US | disclosed |
| US-7514463-B2 | Lonidamine analogues and their use in male contraception and cancer treatment | UNIVERSITY OF KANSAS (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514463-B2 | Lonidamine analogues and their use in male contraception and cancer treatment | UNIVERSITY OF KANSAS (US) | 2009-04-07 | — | — | US | disclosed |
| US-7514463-B2 | Lonidamine analogues and their use in male contraception and cancer treatment | UNIVERSITY OF KANSAS (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1786424-A2 | LONIDAMINE ANALOGUES AND THEIR USE IN MALE CONTRACEPTION AND CANCER TREATMENT | The University of Kansas (US) | 2007-05-23 | — | — | EP | disclosed |
| US-20060047126-A1 | Lonidamine analogues and their use in male contraception and cancer treatment | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-03-02 | — | — | US | disclosed |
| WO-2006023704-A2 | LONIDAMINE ANALOGUES AND THEIR USE IN MALE CONTRACEPTION AND CANCER TREATMENT | UNIVERSITY OF KANSAS (US) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060047126-A1 | Lonidamine analogues and their use in male contraception and cancer treatment | TRAP1, HSPE1, HSF1 | NPSR1 2482/4885CYP1A2 3302/4885CYP3A4 4010/4885 |
| US-20130123296-A1 | LONIDAMINE ANALOGUES FOR FERTILITY MANAGEMENT | SHBG, GNRHR, FSHR | NPSR1 307/4885CYP1A2 348/4885CYP3A4 1218/4885 |
| US-20090197911-A1 | LONIDAMINE ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | PKD1, PKD2, RAF1 | NPSR1 2896/4885CYP1A2 4345/4885CYP3A4 3630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.